Oragon-150 Tablet

About Oragon-150 Tablet

Oragon-150 is a 150 mg tablet containing elagolix, a gonadotropin-releasing hormone antagonist. It is used to manage moderate to severe pain linked to endometriosis in women.

There are 8 brands of Elagolix listed in Bangladesh. The lowest listed price is Elagox 150 mg Tablet at ৳ 170.00 per unit.

What is Oragon-150 Tablet?

Oragon-150 150 mg Tablet contains elagolix, a gonadotropin-releasing hormone (GnRH) antagonist. In endometriosis, tissue similar to the lining of the uterus grows outside it, forming lesions on the ovaries, fallopian tubes and nearby areas such as the bowel or bladder. These lesions depend on the hormone estrogen to grow, and they can cause pain during periods, pelvic pain between periods and pain during sex. Elagolix works by blocking GnRH receptors, which helps reduce the hormone signals that support this growth. Oragon-150 is made by Renata PLC. and is taken by mouth.

Uses of Oragon-150

Oragon-150 is used to manage moderate to severe pain associated with endometriosis. Endometriosis can cause pain during periods, pelvic pain between periods, and pain during sexual intercourse. Elagolix belongs to a group of medicines called gonadotropin-releasing hormone antagonists. Whether this medicine suits a particular person, and how long it should be taken, is decided by the doctor after assessing the symptoms and health history.

How to use Oragon-150

Oragon-150 is a tablet taken by mouth. The doctor decides the dose, how often it is taken and how long the course lasts; do not change these on your own. The tablet is usually taken at approximately the same time each day, with or without food. Pregnancy should be excluded before treatment begins, so discuss this with your doctor. If you miss a dose or are unsure about anything, ask your doctor or pharmacist.

Side effects of Oragon-150

Some women notice side effects while taking elagolix. Commonly reported ones include hot flushes and night sweats, headache, nausea, insomnia, absence of periods, anxiety, joint pain, and depression-related reactions or mood changes. Because mood changes and depression can occur, tell your doctor if you feel low, anxious, or have thoughts of harming yourself. This is not a complete list; ask your doctor or pharmacist about any reaction that worries you.

Safety and precautions

Oragon-150 is not for use during pregnancy, and pregnancy should be ruled out before starting it; if pregnancy occurs during treatment, stop the medicine and contact your doctor. It is also not for women with known osteoporosis or severe liver impairment. Elagolix can lower bone mineral density, may affect menstrual bleeding so that pregnancy is harder to recognise, and can cause mood changes. Tell your doctor about your liver health, bone health, other medicines and any mood problems before starting.

Frequently asked questions

Is Oragon-150 safe in pregnancy or breastfeeding?

It is not to be used during pregnancy, and exposure early in pregnancy may raise the risk of early pregnancy loss. If pregnancy happens during treatment, stop it and see your doctor. There is no information on its presence in human milk, so ask your doctor before breastfeeding.

What is Oragon-150 used for and what kind of medicine is it?

It is used to manage moderate to severe pain associated with endometriosis. It contains elagolix, a gonadotropin-releasing hormone (GnRH) antagonist, which works by blocking GnRH receptors and reducing the hormone signals that support endometriosis lesions.

How should Oragon-150 be stored?

Keep the tablets below 30°C, away from light and moisture, and out of the reach of children. Do not use them after the expiry date, and ask your pharmacist if you are unsure how to dispose of unused tablets.

Can I take Oragon-150 with other medicines?

Some medicines can interact with elagolix, including certain heart, stomach, statin and contraceptive medicines. Estrogen-containing contraceptives may become less effective. Tell your doctor or pharmacist about everything you take, and do not start or stop medicines without their advice.

Indications

Elagolix is indicated for the management of moderate to severe pain associated with endometriosis.

Pharmacology

Endometriosis develops when tissue that is similar to the kind that is normally located in the uterus starts to grow outside of the uterus. Such growth leads to various symptoms like pain during periods, pelvic pain between periods, and pain during sexual intercourse. The growths themselves are referred to as lesions and frequently develop on the ovaries, fallopian tubes, and other areas around the uterus, including the bowel or bladder. The growth of these lesions is dependent upon the estrogen hormone.

Elagolix is an orally-administered, nonpeptide small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland Label. Administration of elagolix results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones, estradiol and progesterone.

Dosage & Administration

Exclude pregnancy before starting Elagolix or start Elagolix within 7 days from the onset of menses. Take Elagolix at approximately the same time each day, with or without food.

Initiate treatment with Elagolix 150 mg once daily-
  • Maximum Treatment Duration: 24 months
  • Coexisting Condition: None
Consider initiating treatment with Elagolix 200 mg twice daily-
  • Maximum Treatment Duration: 6 months
  • Coexisting Condition: Dyspareunia
Initiate treatment with Elagolix 150 mg once daily. Use of 200 mg twice daily is not recommended-
  • Maximum Treatment Duration: 6 months
  • Coexisting Condition: Moderate hepatic impairment (Child-Pugh Class B)

Interaction

May potentiate P-gp substrates (eg. Digoxin), CYP2C19 substrates (eg. Dose limit of Omeprazole is upto 40mg daily). May antagonize CYP3A substrates. Antagonizes oral Midazolam, Rosuvastatin; consider increasing their doses. Maybe antagonized by CYP3A inducers. Reduces efcacy with estrogen-containing contraceptives.

Contraindications

Elagolix is contraindicated in women:
  • Who are pregnant
  • Exposure to ORILISSA early in pregnancy may increase the risk of early pregnancy loss.
  • With known osteoporosis because of the risk of further bone loss
  • With severe hepatic impairment because of the risk of bone loss
  • With concomitant use of strong organic anion transporting polypeptide (OATP) 1B1 inhibitors (e.g., cyclosporine and gemfibrozil)

Side Effects

Most common adverse reactions (>5%) in clinical trials included hot flushes and night sweats, headache, nausea, insomnia, amenorrhea, anxiety, arthralgia, depression-related adverse reactions and mood changes.

Pregnancy & Lactation

Exposure to Elagolix early in pregnancy may increase the risk of early pregnancy loss. Use of Elagolix is contraindicated in pregnant women. Discontinue Elagolix if pregnancy occurs during treatment. The limited human data with the use of Elagolix in pregnant women are insufficient to determine whether there is a risk for major birth defects or miscarriage. Although two cases of congenital malformations were reported in clinical trials with Elagolix, no pattern was identified and miscarriages were reported at a similar incidence across treatment groups. There is no information on the presence of elagolix or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production.

There are no adequate animal data on the excretion of Elagolix in milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Elagolix and any potential adverse effects on the breastfed child from Elagolix.

Precautions & Warnings

  • Bone Loss: Dose- and duration-dependent decreases in bone mineral density (BMD) that may not be completely reversible. Assess BMD in women with additional risk factors for bone loss
  • Reduced Ability to Recognize Pregnancy: Elagolix may alter menstrual bleeding, which may reduce the ability to recognize pregnancy. Perform testing if pregnancy is suspected. Discontinue if pregnancy is confirmed
  • Suicidal Ideation and Mood Disorders: Advise patients to seek medical attention for suicidal ideation, suicidal behavior, new onset or worsening depression, anxiety, or other mood changes
  • Hepatic Transaminase Elevations: Dose-dependent elevations in serum alanine aminotransferase (ALT). Counsel patients on signs and symptoms of liver injury
  • Potential for Reduced Efficacy with Estrogen-Containing Contraceptives: Use non-hormonal contraception during treatment and for one week after discontinuing Elagolix.

Overdose Effects

In case of overdose, patients should be monitored for any signs or symptoms of adverse reactions and initiate appropriate symptomatic treatment, as needed.

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Alternative brands of Elagolix

Other brands with the same generic name, cheapest first.

Elagox Tablet

150 mg

Elagolix

Nuvista Pharma Ltd

৳ 170.00 per unit

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.